Q1 2023 Newsletter – Recombinant metabolising enzymes
March 23, 2023 4:00 pm Leave your thoughtsHypha’s Q1 2023 newsletter – Recombinant metabolising enzymes In our Q1 2023 newsletter we focus on Hypha’s recombinant enzymes, in...
View Article
Hypha’s Q1 2023 newsletter – Recombinant metabolising enzymes In our Q1 2023 newsletter we focus on Hypha’s recombinant enzymes, in...
View Article
Metabolism of nitrogen containing five-membered aromatic heterocycles nitrogen containing five membered aromatic heterocycle Highlighting trends in oxidation and glucuronidation of these...
View Article
Metabolism of 2022 FDA approved small molecule drugs – Part 1 Does CYP3A4 still rule? By Julia Shanu-Wilson It won’t...
View Article
Hypha’s Q4 2022 newsletter – synthesis of deuterated metabolites In our Q4 2022 newsletter we look at how Hypha make...
View Article
AhR activators – friend or foe? A very usual metabolite, a very unusual pharmacological target, and an unexpected serious adverse...
View Article
Metabolism of covalent drugs: Stories from a resurgent field By Samuel Coe With the successful launch of Amgen’s targeted KRAS-blocking...
View Article
Hypha’s Q3 2022 newsletter – gut metabolites and unexpected conjugates In Hypha’s Q3 2022 newsletter we feature our new gut...
View Article
Bioisosteres that influence metabolism By Samuel Coe The majority of reviews on the application of bioisosteres are focused on effects...
View Article
Hypha’s Q2 2022 newsletter – GSH conjugates using PolyCYPs enzymes, metabolite purification case studies, and late-stage oxidation kits In Hypha’s...
View Article
Metabolism of t-butyl groups in drugs: t for trouble? By Julia Shanu-Wilson The tert-butyl group is a common group present...
View Article